Business Description
Ardelyx Inc
NAICS : 325412
SIC : 2834
ISIN : US0396971071
Total Employee Number:
489Compare
Compare
Traded in other countries / regions
ARDX.USA41X.GermanyARDX.Mexico Index Membership
Russell 2000Russell 3000 IPO Date
2014-06-19Description
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.1 | |||||
Equity-to-Asset | 0.26 | |||||
Debt-to-Equity | 1.72 | |||||
Debt-to-EBITDA | -10.94 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 0.22 | |||||
Beneish M-Score | -2.51 | |||||
WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 72.5 | |||||
3-Year EBITDA Growth Rate | 32 | |||||
3-Year EPS without NRI Growth Rate | 14.8 | |||||
3-Year FCF Growth Rate | 25.6 | |||||
3-Year Book Growth Rate | 11.3 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 27.05 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 50.89 | |||||
9-Day RSI | 39.08 | |||||
14-Day RSI | 34.18 | |||||
3-1 Month Momentum % | -28.57 | |||||
6-1 Month Momentum % | -35.17 | |||||
12-1 Month Momentum % | -39.02 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.34 | |||||
Quick Ratio | 3.15 | |||||
Cash Ratio | 2.13 | |||||
Days Inventory | 327.01 | |||||
Days Sales Outstanding | 63.82 | |||||
Days Payable | 361.87 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -7.2 | |||||
Shareholder Yield % | -6.63 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 94.37 | |||||
Operating Margin % | -7.86 | |||||
Net Margin % | -12.35 | |||||
EBITDA Margin % | -5.2 | |||||
FCF Margin % | -3.97 | |||||
OCF Margin % | -3.84 | |||||
ROE % | -36.72 | |||||
ROA % | -10.99 | |||||
ROIC % | -20.09 | |||||
3-Year ROIIC % | 23.71 | |||||
ROC (Joel Greenblatt) % | -65.24 | |||||
ROCE % | -6.56 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 14.42 | |||||
PS Ratio | 2.01 | |||||
PB Ratio | 6.16 | |||||
Price-to-Tangible-Book | 6.16 | |||||
EV-to-EBIT | -34.67 | |||||
EV-to-EBITDA | -39.62 | |||||
EV-to-Revenue | 2.06 | |||||
EV-to-Forward-Revenue | 1.29 | |||||
EV-to-FCF | -51.81 | |||||
Price-to-GF-Value | 0.42 | |||||
| Price-to-Net-Current-Asset-Value | 61.75 | |||||
Earnings Yield (Greenblatt) % | -2.88 | |||||
FCF Yield % | -1.88 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ARDX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Ardelyx Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 450.894 | ||
| EPS (TTM) ($) | -0.22 | ||
| Beta | 1.0894 | ||
| 3-Year Sharpe Ratio | 0.16 | ||
| 3-Year Sortino Ratio | 0.27 | ||
| Volatility % | 50.48 | ||
| 14-Day RSI | 34.18 | ||
| 14-Day ATR ($) | 0.16081 | ||
| 20-Day SMA ($) | 3.856 | ||
| 12-1 Month Momentum % | -39.02 | ||
| 52-Week Range ($) | 3.68 - 8.4 | ||
| Shares Outstanding (Mil) | 258.19 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Ardelyx Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Ardelyx Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Fourth quarter earnings conference call for 2026 | 2027-02-19 16:30 | In 163 days | ||
| Annual report for 2026 | 2027-02-19 | In 162 days | ||
| Fourth quarter earnings results for 2026 | 2027-02-19 | In 162 days | ||
| Third quarter earnings conference call for 2026 | 2026-10-30 16:30 | In 51 days | ||
| Third quarter earnings results for 2026 | 2026-10-30 | In 50 days | ||
| Morgan Stanley 24th Annual Global Healthcare Conference | 2026-09-16 07:45 | In 7 days | ||
| Guidance call for 2026 | 2026-09-10 11:30 | In 1 day | ||
| Guidance call for 2026 | 2026-09-09 | 3.78 (+2.72%) | ||
| Second quarter earnings conference call for 2026 | 2026-08-06 16:30 | 4.91 (-2.58%) | ||
| Second quarter earnings results for 2026 | 2026-08-06 | 4.91 (-2.58%) |
Show
Entries
Ardelyx Inc Frequently Asked Questions
What is Ardelyx Inc(ARDX)'s stock price today?
The current price of ARDX is $3.70. The 52 week high of ARDX is $8.40 and 52 week low is $3.68.
When is next earnings date of Ardelyx Inc(ARDX)?
The next earnings date of Ardelyx Inc(ARDX) is 2026-10-30 Est..
Does Ardelyx Inc(ARDX) pay dividends? If so, how much?
Ardelyx Inc(ARDX) does not pay dividend.
Press Release
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers